A carregar...
De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
BACKGROUND: Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). MATERIALS AND METHODS: The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a fully enrolled (2012–2016), observational, prospective...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7011632/ https://ncbi.nlm.nih.gov/pubmed/32043771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0446 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|